^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Urothelial Cancer
    Drug:Zynyz (retifanlimab-dlwr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

    Excerpt:
    ...treatment-naïve metastatic non-small cell lung cancer with high PD-L1 expression (tumor proportion score ≥ 50%) and...
    Trial ID:
    POD1UM-203
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).

    Published date:
    05/19/2021
    Excerpt:
    Eligible pts (≥18 y) had tx-naïve metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (tumor proportion score ≥50%), cisplatin ineligible locally-advanced/metastatic urothelial cancer (UC) with PD-L1 expression (combined positive score ≥10%)...Confirmed RECIST v1.1 responses were observed in all tumor types (Table) and were consistent with published ORR for other CPIs...Retifanlimab demonstrated antitumor activity...
    DOI:
    10.1200/JCO.2021.39.15_suppl.2571
    Trial ID:
    POD1UM-203